Initial observations of 99mtc labelled locked nucleic acids for antisense targeting

Nuclear Medicine Communications

Volumn 25, Issue 11, 2004, Pages 1113-1118

  Zhang, Yumin ^a   He, Jiang ^a   Liu, Guozheng ^a   Venderheyden, Jean Luc ^a   Gupta, Suresh ^a   Rusckowski, Mary ^a   Hnatowich, Donald J ^a  

^a UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL   (United States)

Author keywords

Antisense; Locked nucleic acid

Indexed keywords

COMPLEMENTARY DNA; DIAGNOSTIC AGENT; RADIOPHARMACEUTICAL AGENT; TECHNETIUM; S ACETYLMERCAPTOACETYLTRIGLYCINE; TECHNETIUM 99M; UNCLASSIFIED DRUG;

ARTICLE; CELL LINE; CHEMISTRY; GENE TARGETING; GENETICS; HUMAN; ISOTOPE LABELING; KIDNEY TUMOR; METABOLIC CLEARANCE RATE; METABOLISM; METHODOLOGY; PILOT STUDY; SCINTISCANNING; CONTROLLED STUDY; DISSOCIATION CONSTANT; DNA HYBRIDIZATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN CELL; IN VITRO STUDY; KINETICS; NUCLEIC ACID PROBE; RADIOCHEMISTRY; SURFACE PLASMON RESONANCE;

CELL LINE; DNA, ANTISENSE; GENE TARGETING; HUMANS; ISOTOPE LABELING; KIDNEY NEOPLASMS; METABOLIC CLEARANCE RATE; PILOT PROJECTS; RADIOPHARMACEUTICALS; TECHNETIUM;

EID: 8444246751     PISSN: 01433636     EISSN: 14735628     Source Type: Journal    
DOI: 10.1097/00006231-200411000-00008     Document Type: Article

References (18)

1. Hnatowich DJ, Winnard Jr P, Virzi F, Fogarasi M, Sano T, Smith CL, et al. Technetium-99m labeling of DNA oligonucleotides. J Nucl Med 1995; 36:2306-2314.
2. Mardirossian G, Lei K, Rusckowski M, Chang F, Qu T, Egholm M, Hnatowich DJ. In vivo hybridization of technetium-99m-labeled peptide nucleic acid (PNA). J Nucl Med 1997; 38:907-913.
3. 99mTc-labeled morpholinos for radiopharmaceutical applications. Eur J Nucl Med 2001; 28:1682-1689.
4. Hnatowich DJ. Antisense and nuclear medicine. J Nucl Med 1999; 40:693-703.
5. Petersen M, Wengel J. LNA: a versatile tool for therapeutics and genomics. Trends Biotechnol 2003; 21:74-81.
6. Kurreck J, Wyszko E, Gillen C, Erdmann VA. Design of antisense oligonucleotides stabilized by locked nucleic acids. Nucleic Acids Res 2002; 30:1911-1918.
7. Christensen U, Jacobsen N, Rajwanshi VK, Wengel J, Koch T. Stopped-flow kinetics of locked nucleic acid (LNA)-oligonucleotide duplex formation: studies of LNA-DNA and DNA-DNA interactions. Biochem J 2001; 354:481-484.
8. Zhang Y-M, Wang Y, Liu N, Zhu Z-H, Rusckowski M, Hnatowich DJ. In vitro investigations of tumor targeting with Tc-99m labeled antisense DNA. J Nucl Med 2001; 42:1660-1669.
9. 3 for technetium-99m labeling of DNA. Nucl Med Biol 1997; 24:425-432.
10. 99mTc attached to antisense DNA. Eur J Nucl Med 2000; 27:1700-1707.
11. Wang Y, Chang F, Zhang Y-M, Liu N, Liu G-Z, Gupta S, et al. Pretargeting with amplification using polymeric peptide nucleic acid (PNA). Bioconjugate Chem 2001; 12:807-816.
12. 99mTc. Nucl Med Biol 2003; 30:207-214.
13. Lappalainen K, Urtti A, Söderling E, Jääskeläinen I, Syrjänen K, Syrjänen S. Cationic liposomes improve stability and intracellular delivery of antisense oligonucleotides into CaSki cells. Biochim Biophys Acta 1994; 1196:201-208.
14. 99mTc-antisense oligonucleotide in target tumor cells. Cancer Biother Radiopharm 2001; 16:411-419.
15. 99mTc- antisense DNAs without entrapment. Mol Imaging Biol 2003; 5:240-247.
16. Hnatowich DJ, Mardirossian G, Fogarasi M, Sano T, Smith CL, Cantor CR, et al. Comparative properties of a technetium-99m-labeled single-stranded natural DNA and a phosphorothioate derivative in vitro and in vivo in mice. Pharm Exp Therap 1996; 276:326-334.
17. Hnatowich DJ. Antisense and nuclear medicine. Where are we now? Cancer Biother Radiopharm 2000; 15:447-457.
18. Nakamura K, Liu G, Zhang Y, Kubo A, Hnatowich DJ. Antisense targeting of P-glycoprotein MDR expression in tissue culture. J Nucl Med 2003; 44:304P.